AB-729

nucleos(t)ide analogue · Arbutus Biopharma Corporation

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AB-729, covering 2025-10-22 to 2026-04-29. Get the full timeline:

Most recent: Clinical Trial Results: Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection [Phase 2]

See pricing